Fibrinolysis Pathways and Clinical Modulation

Core Fibrinolytic Mechanism

The fibrinolytic system operates through a tightly regulated enzymatic cascade, where plasminogen activators convert plasminogen to plasmin, which then cleaves and solubilizes crosslinked fibrin clots into fibrin degradation products, including D-dimer, with fibrin serving as a critical cofactor enhancing tPA activity 1, 2, 3
Plasminogen activators, such as tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA), have distinct roles in converting plasminogen to plasmin, with tPA binding to lysine residues on fibrin with high affinity 3, 4

Recombbinant tPA is the primary agent for reversing thrombotic occlusion in acute stroke, myocardial infarction, and pulmonary embolism, according to the American Heart Association 6

Tranexamic acid (TXA) is used to decrease fibrinolytic rate and reduce bleeding in trauma and post-partum hemorrhage, as recommended by the American College of Obstetricians and Gynecologists 6, 7, 8
TXA and ε-aminocaproic acid are lysine analogs that competitively inhibit plasminogen binding to fibrin, preventing plasmin generation 7, 8

Laboratory monitoring relies primarily on D-dimer and fibrinogen measurements, with global point-of-care testing not widely implemented, according to the International Society on Thrombosis and Haemostasis 1
Plasma-based assays, such as euglobulin clot lysis time (ECLT) and plasminogen activator-induced clot lysis time (PA-CLT), estimate endogenous tPA activity and assess overall fibrinolytic susceptibility 7
Whole blood assays, such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), provide point-of-care measures within 60 minutes, capturing contributions of cellular components 8